title: Letter by Hjemdahl et al regarding article, "Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial".
authors.forename: Paul
authors.initials: P
authors.lastname: Hjemdahl
authors.forename: Hans
authors.initials: H
authors.lastname: Johnsson
authors.forename: N Håkan
authors.initials: NH
authors.lastname: Wallén
mesh_terms: D000925:Anticoagulants / Q000009:adverse effects*; D001562:Benzimidazoles / Q000009:adverse effects*; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced*; D006801:Humans; D008297:Male; D013923:Thromboembolism / Q000188:drug therapy*; D014859:Warfarin / Q000009:adverse effects*; D015091:beta-Alanine / Q000031:analogs & derivatives*
chemical_list: D000925:Anticoagulants; D001562:Benzimidazoles; D015091:beta-Alanine; D014859:Warfarin